Over the last 5 years payer requirements increased exponentially in complexity along different types of new molecules, from cell to gene and combination treatments, and situations, from orphan status to molecules with a degree of uncertainty or complex competitor presentation.

During the same time there has also been a push for affordability and tighter management of levels of access of already launch molecules. As demands evolve, timely access to health technology innovation requires targeted decision planning support.